OBJECTIVES: We used functional MRI (fMRI), transcranial Doppler ultrasound, and visual evoked potentials (VEPs) to determine the nature of blood flow responses to functional brain activity and carbon dioxide (CO2) inhalation in patients with cerebral amyloid angiopathy (CAA), and their association with markers of CAA severity. METHODS: In a cross-sectional prospective cohort study, fMRI, transcranial Doppler ultrasound CO2 reactivity, and VEP data were compared between 18 patients with probable CAA (by Boston criteria) and 18 healthy controls, matched by sex and age. Functional MRI consisted of a visual task (viewing an alternating checkerboard pattern) and a motor task (tapping the fingers of the dominant hand). RESULTS: Patients with CAA had lower amplitude of the fMRI response in visual cortex compared with controls (p = 0.01), but not in motor cortex (p = 0.22). In patients with CAA, lower visual cortex fMRI amplitude correlated with higher white matter lesion volume (r = -0.66, p = 0.003) and more microbleeds (r = -0.78, p < 0.001). VEP P100 amplitudes, however, did not differ between CAA and controls (p = 0.45). There were trends toward reduced CO2 reactivity in the middle cerebral artery (p = 0.10) and posterior cerebral artery (p = 0.08). CONCLUSIONS: Impaired blood flow responses in CAA are more evident using a task to activate the occipital lobe than the frontal lobe, consistent with the gradient of increasing vascular amyloid severity from frontal to occipital lobe seen in pathologic studies. Reduced fMRI responses in CAA are caused, at least partly, by impaired vascular reactivity, and are strongly correlated with other neuroimaging markers of CAA severity.
OBJECTIVES: We used functional MRI (fMRI), transcranial Doppler ultrasound, and visual evoked potentials (VEPs) to determine the nature of blood flow responses to functional brain activity and carbon dioxide (CO2) inhalation in patients with cerebral amyloid angiopathy (CAA), and their association with markers of CAA severity. METHODS: In a cross-sectional prospective cohort study, fMRI, transcranial Doppler ultrasound CO2 reactivity, and VEP data were compared between 18 patients with probable CAA (by Boston criteria) and 18 healthy controls, matched by sex and age. Functional MRI consisted of a visual task (viewing an alternating checkerboard pattern) and a motor task (tapping the fingers of the dominant hand). RESULTS:Patients with CAA had lower amplitude of the fMRI response in visual cortex compared with controls (p = 0.01), but not in motor cortex (p = 0.22). In patients with CAA, lower visual cortex fMRI amplitude correlated with higher white matter lesion volume (r = -0.66, p = 0.003) and more microbleeds (r = -0.78, p < 0.001). VEP P100 amplitudes, however, did not differ between CAA and controls (p = 0.45). There were trends toward reduced CO2 reactivity in the middle cerebral artery (p = 0.10) and posterior cerebral artery (p = 0.08). CONCLUSIONS: Impaired blood flow responses in CAA are more evident using a task to activate the occipital lobe than the frontal lobe, consistent with the gradient of increasing vascular amyloid severity from frontal to occipital lobe seen in pathologic studies. Reduced fMRI responses in CAA are caused, at least partly, by impaired vascular reactivity, and are strongly correlated with other neuroimaging markers of CAA severity.
Authors: Karen J Ferguson; Joanna M Wardlaw; C Louise Edmond; Ian J Deary; Alasdair M J Maclullich Journal: J Neuroimaging Date: 2005-01 Impact factor: 2.486
Authors: Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: Andrew Dumas; Gregory A Dierksen; M Edip Gurol; Amy Halpin; Sergi Martinez-Ramirez; Kristin Schwab; Jonathan Rosand; Anand Viswanathan; David H Salat; Jonathan R Polimeni; Steven M Greenberg Journal: Ann Neurol Date: 2012-07 Impact factor: 10.422
Authors: J V Ly; G A Donnan; V L Villemagne; J A Zavala; H Ma; G O'Keefe; S J Gong; R M Gunawan; T Saunder; U Ackerman; H Tochon-Danguy; L Churilov; T G Phan; C C Rowe Journal: Neurology Date: 2010-02-09 Impact factor: 9.910
Authors: Christopher M Holland; Eric E Smith; Istvan Csapo; Mahmut Edip Gurol; Douglas A Brylka; Ronald J Killiany; Deborah Blacker; Marilyn S Albert; Charles R G Guttmann; Steven M Greenberg Journal: Stroke Date: 2008-02-21 Impact factor: 7.914
Authors: Rebecca J Williams; Bradley G Goodyear; Stefano Peca; Cheryl R McCreary; Richard Frayne; Eric E Smith; G Bruce Pike Journal: J Cereb Blood Flow Metab Date: 2017-02-01 Impact factor: 6.200
Authors: Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Anna M van Opstal; Sanneke van Rooden; Thijs van Harten; Eidrees Ghariq; Gerda Labadie; Panagiotis Fotiadis; M Edip Gurol; Gisela M Terwindt; Marieke J H Wermer; Mark A van Buchem; Steven M Greenberg; Jeroen van der Grond Journal: Lancet Neurol Date: 2016-12-16 Impact factor: 44.182
Authors: Laibaik Park; Kenzo Koizumi; Sleiman El Jamal; Ping Zhou; Mary Lou Previti; William E Van Nostrand; George Carlson; Costantino Iadecola Journal: Stroke Date: 2014-04-29 Impact factor: 7.914
Authors: Susanne J van Veluw; Steven S Hou; Maria Calvo-Rodriguez; Michal Arbel-Ornath; Austin C Snyder; Matthew P Frosch; Steven M Greenberg; Brian J Bacskai Journal: Neuron Date: 2019-12-03 Impact factor: 17.173
Authors: J De Reuck; F Auger; N Durieux; V Deramecourt; C Cordonnier; F Pasquier; C A Maurage; D Leys; R Bordet Journal: Aging Dis Date: 2015-11-17 Impact factor: 6.745
Authors: Panagiotis Fotiadis; Sanneke van Rooden; Jeroen van der Grond; Aaron Schultz; Sergi Martinez-Ramirez; Eitan Auriel; Yael Reijmer; Anna M van Opstal; Alison Ayres; Kristin M Schwab; Trey Hedden; Jonathan Rosand; Anand Viswanathan; Marieke Wermer; Gisela Terwindt; Reisa A Sperling; Jonathan R Polimeni; Keith A Johnson; Mark A van Buchem; Steven M Greenberg; M Edip Gurol Journal: Lancet Neurol Date: 2016-05-11 Impact factor: 44.182